Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects.
Komoroski, B.; Vachharajani, N.; Boulton, D.; Kornhauser, D.; Geraldes, M.; Li, L.; Pfister, M.; Clinical Pharmacology & Therapeutics, 2009, vol. 85, issue 5, p 520, ISSN 00099236. ISBN 15326535.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef